Zinc-α2-glycoprotein exerts antifibrotic effects in kidney and heart

Journal of the American Society of Nephrology

Volumn 26, Issue 11, 2015, Pages 2659-2668

  Sörensen Zender, Inga ^a   Bhayana, Sagar ^a   Susnik, Nathan ^a   Rolli, Veronique ^b   Batkai, Sandor ^a   Baisantry, Arpita ^a   Bahram, Siamak ^b   Sen, Payel ^a   Teng, Beina ^a   Lindner, Robert ^a   Schiffer, Mario ^a   Thum, Thomas ^a,c   Melk, Anette ^a   Haller, Hermann ^a   Schmitt, Roland ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 GLYCOPROTEIN; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ZINC ALPHA2 GLYCOPROTEIN; AZGP1 PROTEIN, HUMAN; CARRIER PROTEIN; GLYCOPROTEIN; SEMINAL PLASMA PROTEIN; ZN-ALPHA-2-GLYCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CONSTRICTION; ARTICLE; CELL ACTIVATION; CELL DEDIFFERENTIATION; CONTROLLED STUDY; DISEASE COURSE; ENDOCYTOSIS; FIBROBLAST; GENE DELETION; HEART; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART STRESS; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERSTITIAL NEPHRITIS; KIDNEY; KIDNEY EPITHELIUM; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY TUBULE CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SYSTEMIC THERAPY; THORACIC AORTA; ANIMAL; AORTA; CARDIAC MUSCLE; CELL DIFFERENTIATION; CHEMISTRY; CHRONIC KIDNEY FAILURE; EPITHELIUM; FIBROSIS; GENETICS; HEK293 CELL LINE; KIDNEY DISEASE; MALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROTEIN SYNTHESIS; URETER OBSTRUCTION;

ANIMALS; AORTA; CARRIER PROTEINS; CELL DIFFERENTIATION; EPITHELIUM; FIBROBLASTS; FIBROSIS; GENE DELETION; GLYCOPROTEINS; HEK293 CELLS; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MALE; MICE; MYOCARDIUM; PHOSPHORYLATION; PROTEIN BIOSYNTHESIS; RATS; RECOMBINANT PROTEINS; SEMINAL PLASMA PROTEINS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; URETERAL OBSTRUCTION;

EID: 84946023526     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014050485     Document Type: Article

References (43)

1. Farris AB, Colvin RB: Renal interstitial fibrosis: Mechanisms and evaluation. Curr Opin Nephrol Hypertens 21: 289-300, 2012
2. Schmitt R, Marlier A, Cantley LG: Zag expression during aging suppresses proliferation after kidney injury. J Am Soc Nephrol 19: 2375 2383, 2008
3. BurgiW, Schmid K: Preparation and properties of Zn-alpha 2-glycoprotein of normal human plasma. J Biol Chem 236: 1066-1074, 1961
4. Hassan MI, Waheed A, Yadav S, Singh TP, Ahmad F: Zinc alpha 2-glycoprotein: A multidisciplinary protein. Mol Cancer Res 6: 892 906, 2008
5. Rolli V, Radosavljevic M, Astier V, Macquin C, Castan-Laurell I, Visentin V, Guigné C, Carpéné C, Valet P, Gilfillan S, Bahram S: Lipolysis is altered in MHC class I zinc-alpha(2)-glycoprotein deficient mice. FEBS Lett 581: 394-400, 2007
6. Hirai K, Hussey HJ, Barber MD, Price SA, Tisdale MJ: Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. Cancer Res 58: 2359-2365, 1998
7. Russell ST, Tisdale MJ: Role of b-adrenergic receptors in the antiobesity and anti-diabetic effects of zinc-a2-glycoprotien (ZAG). Biochim Biophys Acta 1821: 590-599, 2012
8. Bing C, Bao Y, Jenkins J, Sanders P, Manieri M, Cinti S, Tisdale MJ, Trayhurn P: Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Proc Natl Acad Sci U S A 101: 2500-2505, 2004
9. Russell ST, Tisdale MJ: Mechanism of attenuation of skeletal muscle atrophy by zinc-alpha2-glycoprotein. Endocrinology 151: 4696-4704, 2010
10. Ekman R, Johansson BG, Ravnskov U: Renal handling of Zn-alpha2 glycoprotein as compared with that of albumin and the retinol-binding protein. J Clin Invest 57: 945-954, 1976
11. Leal VO, Lobo JC, Stockler-Pinto MB, Farage NE, Velarde GC, Fouque D, Leite M Jr., Mafra D: Zinc-a2-glycoprotein: Is there association between this new adipokine and body composition in hemodialysis patients? Ren Fail 34: 1062-1067, 2012
12. Philipp A, Kralisch S, Bachmann A, Lossner U, Kratzsch J, Blüher M, Stumvoll M, Fasshauer M: Serum levels of the adipokine zinc-a2 glycoprotein are increased in chronic hemodialysis. Metabolism 60: 669-672, 2011
13. Sörensen-Zender I, Beneke J, Schmidt BM, Menne J, Haller H, Schmitt R: Zinc-alpha2-glycoprotein in patients with acute and chronic kidney disease. BMC Nephrol 14: 145, 2013
14. Pelletier CC, Koppe L, Croze ML, Kalbacher E, Vella RE, Guebre Egziabher F,Géloën A, Badet L, FouqueD, Soulage CO:White adipose tissue overproduces the lipid-mobilizing factor zinc a2-glycoprotein in chronic kidney disease. Kidney Int 83: 878-886, 2013
15. Leal VO, Lobo JC, Stockler-Pinto MB, Farage NE, Abdalla DS, Leite M Jr., Mafra D: Is zinc-a2-glycoprotein a cardiovascular protective factor for patients undergoing hemodialysis? Clin Chim Acta 413: 616-619, 2012
16. Zeisberg M, Kalluri R: Cellular mechanisms of tissue fibrosis. 1. Common and organ-specificmechanisms associated with tissue fibrosis.Am J Physiol Cell Physiol 304: C216-C225, 2013
17. Lan HY: Diverse roles of TGF-b/Smads in renal fibrosis and inflammation. Int J Biol Sci 7: 1056-1067, 2011
18. Koesters R, Kaissling B, Lehir M, Picard N, Theilig F, Gebhardt R, Glick AB, Hähnel B, Hosser H, Gröne HJ, Kriz W: Tubular overexpression of transforming growth factor-beta1 induces autophagy and fibrosis but not mesenchymal transition of renal epithelial cells. Am J Pathol 177: 632-643, 2010
19. Ishibe S, Cantley LG: Epithelial-mesenchymal-epithelial cycling in kidney repair. Curr Opin Nephrol Hypertens 17: 379-385, 2008
20. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, RayfordW, BergerheimU, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR: Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 101: 811-816, 2004
21. Huang CY, Zhao JJ, Lv L, Chen YB, Li YF, Jiang SS, Wang W, Pan K, Zheng Y, Zhao BW, Wang DD, Chen YM, Yang L, Zhou ZW, Xia JC: Decreased expression of AZGP1 is associated with poor prognosis in primary gastric cancer. PLoS ONE 8: e69155, 2013
22. Parris TZ, Kovács A, Aziz L, Hajizadeh S, Nemes S, Semaan M, Forssell Aronsson E, Karlsson P, Helou K: Additive effect of the AZGP1, PIP, S100A8 and UBE2C molecular biomarkers improves outcome prediction in breast carcinoma. Int J Cancer 134: 1617-1629, 2014
23. Brysk MM, Lei G, Adler-Storthz K, Chen Z, Brysk H, Tyring SK, Arany I: Zinc-alpha2-glycoprotein expression as a marker of differentiation in human oral tumors. Cancer Lett 137: 117-120, 1999
24. Kong B, Michalski CW, Hong X, Valkovskaya N, Rieder S, Abiatari I, Streit S, Erkan M, Esposito I, Friess H, Kleeff J: AZGP1 is a tumor suppressor in pancreatic cancer inducing mesenchymal-to-epithelial transdifferentiation by inhibiting TGF-b-mediated ERK signaling. Oncogene 29: 5146-5158, 2010
25. Russell ST, Tisdale MJ: Role of b-adrenergic receptors in the oral activity of zinc-a2-glycoprotein (ZAG). Endocrinology 153: 4696-4704, 2012
26. De Wever O, Mareel M: Role of tissue stroma in cancer cell invasion. J Pathol 200: 429-447, 2003
27. Bascands JL, Schanstra JP: Obstructive nephropathy: Insights from genetically engineered animals. Kidney Int 68: 925-937, 2005
28. Zhou L, Fu P,Huang XR, Liu F, Chung AC, Lai KN, LanHY:Mechanismof chronic aristolochic acid nephropathy: Role of Smad3. Am J Physiol Renal Physiol 298: F1006-F1017, 2010
29. Xia Y, Lee K, Li N, Corbett D, Mendoza L, Frangogiannis NG: Characterization of the inflammatory and fibrotic response in a mouse model of cardiac pressure overload. Histochem Cell Biol 131: 471-481, 2009
30. Buijs JT, Henriquez NV, van Overveld PG, van der Horst G, ten Dijke P, van der Pluijm G: TGF-beta and BMP7 interactions in tumour progression and bone metastasis. Clin Exp Metastasis 24: 609-617, 2007
31. Selva DM, Lecube A, Hernández C, Baena JA, Fort JM, Simó R: Lower zinc-alpha2-glycoprotein production by adipose tissue and liver in obese patients unrelated to insulin resistance. J Clin Endocrinol Metab 94: 4499-4507, 2009
32. Gong FY, Zhang SJ, Deng JY, Zhu HJ, Pan H, Li NS, Shi YF: Zinc-alpha2 glycoprotein is involved in regulation of body weight through inhibition of lipogenic enzymes in adipose tissue. Int JObes(Lond) 33: 1023-1030, 2009
33. Zhu HJ, Wang XQ, Pan H, Gong FY, Zhang DX, Li NS, Wang LJ, Yang HB: Serumlevels of the adipokine zinc- a 2-glycoprotein are decreased in patients with hypertension. ISRN Endocrinol 2014: 374090, 2014
34. Ceperuelo-Mallafré V, Escoté X, Viladés C, Peraire J, Domingo P, Solano E, Sirvent JJ, Pastor R, Tinahones F, LealM, RichartC, Vendrell J, Vidal F, Alba V, Aguilar A, Auguet T, Chacón MR, López-Dupla M, Megia A, Miranda M, Olona M, Saurí A, Vargas M, Velasco I, Veloso S, Fontanet A, Gutiérrez M, Mateo G, Muñoz J, Sambeat MA; HIV-1 Lipodystrophy Study Group: Zinc alpha-2 glycoprotein is implicated in dyslipidaemia in HIV-1-infected patients treated with antiretroviral drugs. HIV Med 13: 297-303, 2012
35. Stepan H, Philipp A, Roth I, Kralisch S, Jank A, Schaarschmidt W, Lössner U, Kratzsch J, BlüherM, Stumvoll M, FasshauerM: Serumlevels of the adipokine zinc-a2-glycoprotein are increased in preeclampsia. J Endocrinol Invest 35: 562-565, 2012
36. Tedeschi S, Pilotti E, Parenti E, Vicini V, Coghi P,Montanari A, Regolisti G, Fiaccadori E, Cabassi A: Serum adipokine zinc a2-glycoprotein and lipolysis in cachectic and noncachectic heart failure patients: Relationship with neurohormonal and inflammatory biomarkers. Metabolism 61: 37-42, 2012
37. Gangadharan B, Antrobus R, Dwek RA, Zitzmann N: Novel serum biomarker candidates for liver fibrosis in hepatitis C patients. Clin Chem 53: 1792-1799, 2007
38. McIntyre CW, Odudu A: Hemodialysis-associated cardiomyopathy: A newly defined disease entity. Semin Dial 27: 87-97, 2014
39. Silver J, Rodriguez M, Slatopolsky E: FGF23 and PTH-double agents at the heart of CKD. Nephrol Dial Transplant 27: 1715-1720, 2012
40. Wargent ET, O'Dowd JF, Zaibi MS, Gao D, Bing C, Trayhurn P, Cawthorne MA, Arch JR, Stocker CJ: Contrasts between the effects of zinc-a2-glycoprotein, a putative b3/2-adrenoceptor agonist and the b3/2-adrenoceptor agonist BRL35135 in C57Bl/6 (ob/ob) mice. J Endocrinol 216: 157-168, 2013
41. Sörensen I, Susnik N, Inhester T, Degen JL, MelkA,Haller H, Schmitt R: Fibrinogen acting as a mitogen for tubulointerstitial fibroblasts, promotes renal fibrosis. Kidney Int 80: 1035-1044, 2011
42. Susnik N, Sörensen-Zender I, Rong S, von Vietinghoff S, Lu X, Rubera I, TaucM, Falk CS, Alexander WS,Melk A, Haller H, Schmitt R: Ablation of proximal tubular suppressor of cytokine signaling 3 enhances tubular cell cycling and modifies macrophage phenotype during acute kidney injury. Kidney Int 85: 1357-1368, 2014
43. Rockman HA, Ross RS, Harris AN, Knowlton KU, SteinhelperME, Field LJ, Ross J Jr., Chien KR: Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivomurinemodel of cardiac hypertrophy. Proc Natl Acad Sci U S A 88: 8277-8281, 1991